NCT04355858: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+, AR+
Other Mutations: NF1/2, BRCA+, HER2, PDGFR, PI3K, Akt, mTOR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody, Immunotherapy, Serine-Threonine Kinase Inhibitor, Misc Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, untreated, or actively progressing CNS metastases – see trial for details

Comments are closed.

Up ↑